IV Nurse Week 2026
Build an infusion system that keeps every therapy visible from access to outcome.
Infusion reliability is an enterprise operating issue.
Infusion nurses connect device selection, vascular access, therapy delivery, surveillance, escalation, education, and transition. Those connections cross inpatient units, procedural areas, ambulatory centers, home infusion, pharmacy, infection prevention, and supply operations.
INS broadened the former IV Nurse Day into IV Nurse Week in 2026. The expanded observance creates a practical executive checkpoint: can leaders see the full infusion route, the owner at each handoff, and the risks that remain open?
Govern infusion therapy as one system across settings, with shared definitions, visible ownership, and a closed escalation loop.
National 2024 change compared with 2023.
states and territories performed better than the 2015 acute care CLABSI baseline.
U.S. hospital patients contracts at least one healthcare-associated infection on a given day.
average registered nurse openings projected annually from 2024 through 2034.
Sources: CDC 2024 HAI Progress Report and U.S. Bureau of Labor Statistics. The 1-in-38 estimate covers all healthcare-associated infections, not only infusion-related events. BLS data cover all registered nurses, not only infusion nurses.
Keep therapy intent, device status, and ownership connected.
At every stage, define the accountable role, required information, response standard, and escalation threshold. Local clinical policy and current standards should determine the detailed practice.
-
Assess need
Make indication, duration, setting, patient factors, and alternatives visible.
-
Select access
Align the device and access plan with the therapy, expected duration, and care setting.
-
Insert safely
Use qualified personnel, defined competency, supplies, documentation, and escalation.
-
Verify setup
Confirm the order, device, line, medication, pump setup, and readiness before delivery.
-
Deliver therapy
Connect administration data, smart technology, line management, and response.
-
Monitor and transition
Reassess need, surface complications, educate, and hand unresolved work to the next owner.
Operating rule: no device concern, therapy variance, complication signal, or transition gap should leave the route without a named owner and documented next action.
See risk before it becomes an event.
Choose a compact set of measures that can trigger action. Pair every metric with an owner, threshold, review cadence, and escalation path.
Need and device fit
Track device utilization, therapy-to-device alignment, avoidable dwell days, and devices without a current documented indication.
Insertion and maintenance
Track observed bundle reliability, line rounds, dressing and tubing compliance, and corrective actions that remain open.
Delivery reliability
Track smart-pump library use, alert overrides, infusion interruptions, delays, equipment availability, and recall readiness.
Complication and transition
Track CLABSI, peripheral device complications, escalation response, education, and home or ambulatory handoff closure.
INS describes its Standards of Practice as expectations for safe, consistent infusion care across patient populations and settings where vascular access devices are inserted or managed and infusion therapies are administered. Dashboard definitions should follow current standards and the organization’s validated surveillance methods.
Make the infusion plan executable for the next team.
A device note alone is not a handoff. The transition is complete when therapy intent, device status, current delivery setup, unresolved concerns, and the next owner move together.
Preserve therapy and device context
- State the therapy, indication, expected duration, and current plan.
- Identify the device, site, insertion details, access limitations, and latest assessment.
- Carry forward pump, rate, line, tubing, medication, and pending-dose information.
- Name open concerns, monitoring needs, escalation status, and the receiving owner.
Make continued care workable
- Confirm the receiving service, supplies, medication access, equipment, and contact route.
- Transmit the therapy plan, device record, current assessment, and monitoring schedule.
- Verify patient and caregiver education using the organization’s approved method.
- Document open risks, response instructions, follow-up timing, and accountable owner.
Governance boundary: This is an executive workflow model, not a bedside procedure. Clinical teams should follow current standards, manufacturer instructions, organizational policy, and applicable scope-of-practice requirements.
Measure reliability across the whole route.
Use stable definitions and denominators, stratify by setting and population, and distinguish leading process signals from clinical and operating outcomes.
| Domain | Leading measure | Outcome measure | Executive question |
|---|---|---|---|
| Need and selection | Devices with current indication and documented therapy-to-device fit | Avoidable dwell days and unplanned device replacement | Are we using the right access for the current need? |
| Insertion and maintenance | Observed reliability against locally adopted bundles | Device complications using stable definitions and denominators | Where does practice variation persist? |
| Infection | Line review completion and corrective actions closed on time | CLABSI SIR and rate, stratified by relevant location and device | Do leaders see both process reliability and infection outcomes? |
| Delivery and technology | Drug-library use, alert review, and equipment readiness | Infusion delay, interruption, or harm associated with delivery | Can technology risks reach a patient before action? |
| Transition and home | Handoffs with complete plan, education, supplies, and next owner | Escalations, delays, or unplanned care after transition | Does ownership survive the care-setting boundary? |
| Workforce and competency | Validated competency, coverage, vacancy, and skill mix by setting | Service gaps, workarounds, or capacity loss | Is qualified expertise available where risk concentrates? |
Repair one high-risk break, then spread the method.
Use IV Nurse Week to start a bounded operating improvement with visible sponsorship, baseline measures, and a decision point at the end of the quarter.
See the route
- Name the executive sponsor and infusion-system owner.
- Map inpatient, procedural, ambulatory, and home interfaces.
- Baseline six measures with stable definitions.
- Select one high-risk handoff and one reliability gap.
Set ownership
- Define decision rights and escalation thresholds.
- Align policy, competencies, documentation, supplies, and technology.
- Agree on device and complication definitions across sites.
- Assign a closed-loop response to each dashboard trigger.
Run the loop
- Pilot the workflow in one service line or transition.
- Publish a compact operating dashboard.
- Review misses, open risks, and corrective actions each week.
- Remove one recurring barrier and decide how to spread.
Recognize infusion nurses by strengthening the system around their expertise.
Recognition becomes operational when infusion teams have the staffing, competencies, supplies, technology, information, and escalation paths to keep therapy visible from access to outcome.
Authoritative resources
- Infusion Nurses Society: IV Nurse Week 2026
- Infusion Nurses Society: Infusion Therapy and Vascular Access Standards of Practice
- CDC: 2024 National and State Healthcare-Associated Infections Progress Report
- CDC NHSN: Bloodstream Infection Event
- AHRQ: CLABSI prevention tools
- FDA: Infusion Pumps
- U.S. Bureau of Labor Statistics: Registered Nurses
Reviewed August 2026. INS lists IV Nurse Week for January 26–30, 2026, with the theme “Igniting Health and Inspiring Hope,” and explains that the former IV Nurse Day expanded into a full week. This corrects legacy calendar listings that identify January 21 as National IV Nurse Day. This brief supports executive planning and education. Scope of practice, competency, device insertion and management, delegation, licensure, organizational policy, standards, and manufacturer instructions vary by jurisdiction, setting, device, and therapy. It does not replace clinical judgment, current standards, legal review, manufacturer instructions, or applicable law. CDC statistics are national benchmarks and do not represent local performance. BLS projections cover all registered nurses, not infusion nurses specifically.